Although lung cancer is only the second most common cancer in the United States, it is by far the deadliest cancer in both men and women. But thanks to advancements in precision medicine, treatments for lung cancer are improving, and many patients are benefiting from these new, targeted therapies.
“When we find we have drugs targeted for a specific genetic mutation driving the cancer, the chance of having someone live longer and feel better is much higher,” says David Jackman, MD, a medical oncologist with Dana-Farber’s Lowe Center for Thoracic Oncology and the institute’s Medical Director for Clinical Pathways. “We’re doubling, tripling, and in some cases quadrupling response rates compared to what we see with traditional chemotherapy.”
In this Cancer Conversations podcast episode, Jackman joins Dana-Farber Chief Scientific Officer Barrett Rollins, MD, PhD, for a discussion on how precision medicine is being used in cancer treatment today as well as some of the latest research in the field.
The Cancer Conversations series features Q&A-style conversations with Dana-Farber physicians, clinicians, and researchers. Topics include breast cancer research, precision cancer medicine, integrative therapies, cancer genetics, and more. Visit the Cancer Conversations page for more episodes and the Dana-Farber podcast page for more cancer podcast series.